Bristol Myers Squibb helmsman Chris Boerner joined a growing list of life sciences leaders announcing major U.S. investments ...

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

The announcement of new investment was first made by CEO Christopher Boerner in an opinion piece published in Stat News on ...

Bristol Myers Squibb Co. said it will spend $40 billion in the US over the next five years, joining a slew of drug companies ...

Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing ...

A new executive order aims to smooth the path for getting U.S. manufacturing facilities up and running; HHS says it will ...

Merck broke ground on a $1B, 470K SF biotech facility last month at the Chestnut Run Innovation & Science Park in Wilmington, ...

The $40 billion investment will be spread across various R&D and manufacturing areas over the next five years.

Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at ...

(Reuters) -Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in ...

The announcement of new investment was first made by CEO Christopher Boerner in an opinion piece published in Stat News on Monday, and was later confirmed to Reuters by a company spokesperson.